Miriplatin is primarily used in the treatment of hepatocellular carcinoma (HCC), a common type of liver cancer. It is administered as a lipiodol-based suspension for transarterial chemoembolization (TACE), a procedure that delivers the drug directly to the tumor site. This targeted approach helps in maximizing the drug's efficacy while minimizing systemic side effects. Miriplatin works by releasing platinum ions that inhibit DNA synthesis in cancer cells, leading to their destruction. Its lipophilic nature allows it to remain localized in the tumor for an extended period, enhancing its therapeutic effect. This makes it a valuable option for patients with unresectable HCC, particularly those who may not tolerate other chemotherapy agents well.